TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Xvivo Perfusion AB
Closing information (x1000 SEK)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover | 415,292 | 258,386 | 179,861 |
Financial expenses | 55,693 | 20,205 | 12,478 |
Earnings before taxes | 22,314 | 6,665 | -57,263 |
EBITDA | 48,576 | -7,460 | |
Total assets | 1,733,084 | 1,542,596 | 1,150,309 |
Current assets | 467,508 | 547,532 | 463,230 |
Current liabilities | 134,896 | 104,519 | 72,248 |
Equity capital | 1,430,136 | 1,285,450 | 1,008,461 |
- share capital | 762 | 754 | 680 |
Employees (average) | 114 | 92 | 63 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency | 82.5% | 83.3% | 87.7% |
Turnover per employee | 3,643 | 2,809 | 2,855 |
Profit as a percentage of turnover | 5.4% | 2.6% | -31.8% |
Return on assets (ROA) | 4.5% | 1.7% | -3.9% |
Current ratio | 346.6% | 523.9% | 641.2% |
Return on equity (ROE) | 1.6% | 0.5% | -5.7% |
Change turnover | 156,906 | 78,525 | -40,976 |
Change turnover % | 61% | 44% | -19% |
Chg. No. of employees | 22 | 29 | 17 |
Chg. No. of employees % | 24% | 46% | 37% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.